Journal: Materials Today Bio
Article Title: Enhanced oral nanomedicine utilizing biomineralized oncolytic virus for synergistic gastrointestinal cancer therapy
doi: 10.1016/j.mtbio.2025.102583
Figure Lengend Snippet: Construction and characterization of CaCO 3 @CM-OA. (A) Particle size analysis of OA, CM-OA, and CaCO 3 @CM-OA. (B) Zeta potential measurements of OA, CM-OA, and CaCO 3 @CM-OA. (C) TEM image of OA and CM-OA, together with SEM image of CaCO 3 @CM-OA. (D) TEM image and corresponding elemental mapping of CaCO 3 @CM-OA. (E, F) Size and PDI of OA, CM-OA, and CaCO3@CM-OA under different pH conditions and time points. (G) Silver-stained SDS-PAGE gel comparing cell membrane, CM-OA, and CaCO 3 @CM-OA. (H) Dot blot assay detecting adenovirus type 5 hexon in OA, CM-OA, and CaCO 3 @CM-OA. (I) Blood and intestinal tissues were collected from mice after oral administration. (J) Relative viral levels in blood at various time points and (K) relative fluorescence intensity in intestinal tissues were quantified. Data are presented as mean ± SD. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001.
Article Snippet: The antibodies used in western blot, immunofluorescence and immunohistochemistry experiments were as follows: CRT (Bioss, 5913R), HMGB1 (Beytime, AF1174), Anti-Adenovirus Type 5 Hexon (abcam, ab816352), Ki67 (Proteintech, 27309-1-AP), p53 (MCE, HY- P80938 ), p-p53 (Affinity, AF3075), p21 (Affinity, AF6290), CyclinB1 (Proteintech, 28603-1-AP), Bcl2 (Proteintech, 26593-1-AP), Bax (Proteintech, 50599-2-Ig), Caspase3 (Proteintech, 19677-1-AP), cleaved-Caspase3 (CST, 9661S), Cytochrome c (Proteintech, 10993-1-AP), p62 (HuaBio, HA721171), Beclin1 (CST, 3495S), LC3A/B (CST, 12741T), p-MLKL (MCE, HY-P81878), MLKL (HuaBio, ET1601-25), N-cadherin (Affinity, AF5239), E-cadherin (Affinity, AF0131), α-SMA (HuaBio, ET1607-53), Vimentin (Affinity, AF7013), Collegen-I (Proteintech, 66761-1-Ig), Collegen-III (Abcam, ab7778).
Techniques: Particle Size Analysis, Zeta Potential Analyzer, Staining, SDS Page, Membrane, Dot Blot, Fluorescence